Axcelead Drug Discovery Partners, Inc.

Overview

Axcelead Drug Discovery Partners is a contract research organization established in 2017 to support healthcare innovation by leveraging Takeda Pharmaceutical's drug discovery research foundation. The company operates as a trusted drug discovery solution provider, serving diverse pharmaceutical players—including domestic pharma, global megapharma, bioventures, and academic institutions—with an integrated discovery platform.

Core Capabilities

Drug Discovery Services:

• Lead generation and lead optimization (LG/LO) with above-industry screening hit rates
• Medicinal chemistry (computational chemistry, parallel synthesis, flow chemistry)
• High-throughput screening (HTS) and phenotypic screening
• iPS cell-based compound screening
• Compound library management and custom small-molecule libraries

Biology & Mechanism:

• Genetically modified mouse and rat creation and evaluation
• Disease model animals (chronic kidney disease models, hydrodynamics-based models)
• Omics services: mechanism exploration, biomarker discovery, bioinformatics
• Single-cell and single-nucleus analysis
• Spatial transcriptomics
• Flow cytometry-based research

Nucleic Acid Therapeutics:

• Off-target effect evaluation for nucleic acid drugs (total service)
• miRNA analysis
• RNA splicing-directed drug discovery

Chemistry & ADMET:

• HT-ADMET and parenteral formulation development
• Development candidate synthesis and modeling/simulation
• Analytical chemistry and synthetic chemistry

Safety & Efficacy:

• In vitro toxicity screening, hERG assays, phototoxicity evaluation
• Cardiovascular safety assessment and mechanism-of-action analysis
• In vivo efficacy and pharmacokinetics/pharmacodynamics studies

Therapeutic Modalities:

• Small molecules (including protein degradation inducers)
• RNA modulators
• Peptide therapeutics
• Nucleic acid drugs
• Regenerative medicine and mRNA therapeutics

Disease Expertise:

• Oncology (cancer immunotherapy drug discovery, tumor microenvironment research, syngeneic transplant models)
• Immunology (flow cytometry-driven research)
• Neurology and neuromuscular disease
• Nephrology (chronic kidney disease)
• Metabolic disease (MASH, obesity)
• Cardiovascular disease (heart failure, echocardiography-based translational bridging)

Client Base & Performance

Axcelead works with nearly all domestic Japanese pharmaceutical companies investing in drug discovery research and maintains significant relationships with global megapharma. The company is positioned as a trusted partner for addressing unmet medical needs in oncology, immunology, and central nervous system disorders. Demonstrated above-industry screening hit rates and project goal achievement rates reflect the expertise of experienced researchers who previously led drug discovery at major pharmaceutical companies.